238000004519 manufacturing process Methods 0.000 description 22. YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 24. 
230000000144 pharmacologic effect Effects 0.000 abstract description 2.
239000004615 ingredient Substances 0.000 abstract description 9. 206010057190 Respiratory tract infection Diseases 0.000 claims 6. KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2. 239000008194 pharmaceutical composition Substances 0.000 claims description 3. 239000002702 enteric coating Substances 0.000 claims description 4. 238000009505 enteric coating Methods 0.000 claims description 4. 239000000654 additive Substances 0.000 claims description 6. 239000003795 chemical substances by application Substances 0.000 claims description 9. 239000011780 sodium chloride Substances 0.000 claims description 10. 239000007884 disintegrant Substances 0.000 claims description 10. 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12. VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims description 12. 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14. 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14. 239000008187 granular material Substances 0.000 claims description 23. 239000004480 active ingredient Substances 0.000 claims description 38. 230000002459 sustained Effects 0.000 claims abstract description 21. 229960004085 mosapride Drugs 0.000 title abstract description 4. YPELFRMCRYSPKZ-UHFFFAOYSA-N Mosapride Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 title abstract description 4. 239000002131 composite material Substances 0.000 title abstract description 6. 
SXTZYIWTRUTYCY-UHFFFAOYSA-N Rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2N=C3C=CC=C3N=2)=C1C SXTZYIWTRUTYCY-UHFFFAOYSA-N 0.000 title claims abstract 8.
238000002360 preparation method Methods 0.000 title claims abstract description 22.229960004157 rabeprazole Drugs 0.000 title claims abstract description 32.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from KR10-2017-0172473 external-priority Application filed by 한국유나이티드제약 주식회사, 사단법인 유나이티드사이언스알앤디센터 filed Critical 한국유나이티드제약 주식회사 Priority to US16/768,805 priority Critical patent/US20210177765A1/en Priority to RU2020118467A priority patent/RU2753697C1/en Priority to CN201880079811.1A priority patent/CN111479559A/en Priority to JP2020552648A priority patent/JP7017647B2/en Publication of WO2019117502A1 publication Critical patent/WO2019117502A1/en Priority to PH12020550806A priority patent/PH12020550806A1/en Links Inventor 김병진 송희용 최연웅 김성엽 Original Assignee 한국유나이티드제약 주식회사 사단법인 유나이티드사이언스알앤디센터 Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents WO2019117502A1 - Core tablet composite preparation comprising mosapride and rabeprazole WO2019117502A1 - Core tablet composite preparation comprising mosapride and rabeprazole
0 kommentar(er)
